GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
55.32
-0.19 (-0.34%)
At close: Mar 10, 2026, 4:00 PM EDT
55.14
-0.18 (-0.33%)
Pre-market: Mar 11, 2026, 5:28 AM EDT
GSK Revenue
GSK had revenue of 8.62B GBP in the quarter ending December 31, 2025, with 6.17% growth.
Revenue (ttm)
32.67B GBP
Revenue Growth
+4.11%
P/S Ratio
2.53
Revenue / Employee
488,727 GBP
Employees
66,841
Market Cap
111.26B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
| Dec 31, 2018 | 30.82B | 635.00M | 2.10% |
| Dec 31, 2017 | 30.19B | 2.30B | 8.24% |
| Dec 31, 2016 | 27.89B | 3.97B | 16.58% |
| Dec 31, 2015 | 23.92B | 917.00M | 3.99% |
| Dec 31, 2014 | 23.01B | -3.50B | -13.20% |
| Dec 31, 2013 | 26.51B | 74.00M | 0.28% |
| Dec 31, 2012 | 26.43B | -956.00M | -3.49% |
| Dec 31, 2011 | 27.39B | -1.01B | -3.54% |
| Dec 31, 2010 | 28.39B | 24.00M | 0.08% |
| Dec 31, 2009 | 28.37B | 4.02B | 16.49% |
| Dec 31, 2008 | 24.35B | 1.64B | 7.20% |
| Dec 31, 2007 | 22.72B | -509.00M | -2.19% |
| Dec 31, 2006 | 23.23B | 1.57B | 7.23% |
| Dec 31, 2005 | 21.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
GSK News
- 16 hours ago - FDA Approves GSK's Wellcovorin for Cerebral Folate Deficiency - GuruFocus
- 18 hours ago - FDA Approves Drug Trump Touted for Autism to Treat Other Neurological Disorder - WSJ
- 18 hours ago - FDA Approves Leucovorin—But Not For Autism, Even After Trump Admin Officials Touted Drug Last Year - Forbes
- 20 hours ago - US FDA approves leucovorin for ultra- rare genetic disorder causing autism-like symptoms - Reuters
- 20 hours ago - FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment - CNBC
- 22 hours ago - Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn - The Guardian
- 1 day ago - Former GlaxoSmithKline HQ in west London to be transformed into 1,500 new homes - Evening Standard
- 2 days ago - GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million - WSJ